KR20240082408A - 인자 viii 키메라 단백질의 제형 및 이의 용도 - Google Patents

인자 viii 키메라 단백질의 제형 및 이의 용도 Download PDF

Info

Publication number
KR20240082408A
KR20240082408A KR1020247015817A KR20247015817A KR20240082408A KR 20240082408 A KR20240082408 A KR 20240082408A KR 1020247015817 A KR1020247015817 A KR 1020247015817A KR 20247015817 A KR20247015817 A KR 20247015817A KR 20240082408 A KR20240082408 A KR 20240082408A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
arginine
sucrose
poloxamer
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015817A
Other languages
English (en)
Korean (ko)
Inventor
타일러 칼라지
랜들 몰딘
티모시 알. 맥코이
로브나 므잘락 타지
Original Assignee
바이오버라티브 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오버라티브 테라퓨틱스 인크. filed Critical 바이오버라티브 테라퓨틱스 인크.
Publication of KR20240082408A publication Critical patent/KR20240082408A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247015817A 2021-10-15 2022-10-14 인자 viii 키메라 단백질의 제형 및 이의 용도 Pending KR20240082408A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
US63/256,432 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
KR20240082408A true KR20240082408A (ko) 2024-06-10

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015817A Pending KR20240082408A (ko) 2021-10-15 2022-10-14 인자 viii 키메라 단백질의 제형 및 이의 용도

Country Status (13)

Country Link
US (1) US20240358800A1 (cg-RX-API-DMAC7.html)
EP (2) EP4415693B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538091A (cg-RX-API-DMAC7.html)
KR (1) KR20240082408A (cg-RX-API-DMAC7.html)
CN (1) CN118103034A (cg-RX-API-DMAC7.html)
AU (1) AU2022366974A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229979A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024004211A2 (cg-RX-API-DMAC7.html)
ES (1) ES3068733T3 (cg-RX-API-DMAC7.html)
IL (1) IL311969A (cg-RX-API-DMAC7.html)
MX (1) MX2024004494A (cg-RX-API-DMAC7.html)
TW (1) TW202334244A (cg-RX-API-DMAC7.html)
WO (1) WO2023064886A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Also Published As

Publication number Publication date
ES3068733T3 (en) 2026-06-02
JP2024538091A (ja) 2024-10-18
EP4740963A2 (en) 2026-05-13
EP4415693A1 (en) 2024-08-21
WO2023064886A1 (en) 2023-04-20
EP4740963A3 (en) 2026-07-22
CA3229979A1 (en) 2023-04-20
EP4415693B1 (en) 2026-02-18
TW202334244A (zh) 2023-09-01
CN118103034A (zh) 2024-05-28
MX2024004494A (es) 2024-07-15
EP4415693C0 (en) 2026-02-18
CO2024004211A2 (es) 2024-04-18
AU2022366974A1 (en) 2024-05-30
US20240358800A1 (en) 2024-10-31
IL311969A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
CN103917554B (zh) 用于改善重构后纯化的因子viii的稳定性的方法
JP7741145B2 (ja) 第ix因子ポリペプチド製剤
JP5784907B2 (ja) 組換え型vwf製剤
EP3793588B1 (en) Methods of treating hemophilia a
WO1995016460A1 (en) Composition containing soluble thrombomodulins
KR20170026580A (ko) 변형된 폰 빌레브란트 인자
RU2426745C2 (ru) Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция
JP2023166014A (ja) コラーゲン7組成物及びそれを用いる方法
EP4358938A1 (en) Formulations of factor viii chimeric proteins and uses thereof
EP4415693B1 (en) Formulations of factor viii chimeric proteins and uses thereof
AU2001293229B2 (en) Thrombomodulin analogs for use in recovery of spinal cord injury
WO2024077335A1 (en) Factor ix variant polypeptides for administration to soft tissue
KR102058864B1 (ko) 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EA051115B1 (ru) Составы на основе химерных белков, содержащих фактор viii, и варианты их применения
WO2024141054A1 (zh) 包含融合蛋白的药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000